Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer’s disease trial
Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026Appoints US-based Chief Commercial Officer, Andrew UdellXanamem's unique ability to control brain cortisol draws widespread